Pricing Log in Create free account

Haleon PLC Sponsored ADR (HLN) vs Neurocrine Biosciences, Inc. (NBIX)

Haleon PLC Sponsored ADR and Neurocrine Biosciences, Inc. are both Drug Manufacturers Specialty & Generic companies. Haleon PLC Sponsored ADR is the larger, with a market value of $40.2B against $16.2B — 2.5× the size. Haleon PLC Sponsored ADR trades at the lower P/E: 20.5× against 23.0×. Neurocrine Biosciences, Inc. has the higher net margin (19.0% vs 11.2%) and the higher return on invested capital (17.7% vs 0.00%). Across the 21 metrics below, Neurocrine Biosciences, Inc. leads on 12 and Haleon PLC Sponsored ADR on 9.

Valuation

Metric HLN NBIX Drug Manufacturers Specialty & Generic median
P/E 20.48 23.01 20.55
P/S 2.32 4.40 2.08
P/B 1.90 4.20 1.79
Price to free cash flow 9.23 15.68 16.29
EV/EBITDA 12.22 16.51 12.22
EV/Sales 2.87 4.35 2.87
Earnings yield 4.88% 4.35% (15.94%)
Free cash flow yield 10.84% 6.38% 0.00%

Profitability

Metric HLN NBIX Drug Manufacturers Specialty & Generic median
Gross margin 62.22% 97.75% 53.51%
Operating margin 17.93% 23.96% 0.00%
Net margin 11.18% 18.98% (2.45%)
Free cash flow margin 0.00% 28.09% 0.00%
Return on equity 0.00% 20.41% (0.80%)
Return on assets 0.00% 14.20% (1.67%)
Return on invested capital 0.00% 17.65% 0.00%

Growth

Metric HLN NBIX Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — 37.98% 5.22%
EPS growth (last fiscal year) 22.50% 41.95% 42.91%
Revenue growth, 5-year CAGR 1.43% 22.29% 7.24%
Net income growth, 5-year CAGR 6.98% 3.28% 0.00%

Health

Metric HLN NBIX Drug Manufacturers Specialty & Generic median
Debt to equity 0.50 0.00 0.04
Current ratio 0.69 2.04 2.41
Net debt to EBITDA 2.63 (2.33) 1.01

Dividend

Metric HLN NBIX Drug Manufacturers Specialty & Generic median
Dividend yield 2.16% — 1.45%
Payout ratio — — 0.27

Size

Metric HLN NBIX Drug Manufacturers Specialty & Generic median
Market cap 40.24b 16.17b 315.39m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack